Maria Willrich, PhD retweeted
Caution: Always interpret serum findings within the clinical context. Read how teclistamab resulted in a false IgG lambda monoclonal band in a patient with known light chain myeloma: buff.ly/wVykPEQ
Commentary: buff.ly/QlbQVlz
@malicewi
@mayoclinic
#JALM
Maria Willrich, PhD retweeted
We are transcending traditional testing for autoimmune neurological conditions. For the last 30 years, we have continued to identify new antibodies and make connections between patterns on tissue immunosuppressants, a disease presentation, and response.
bit.ly/4dYdV68
Maria Willrich, PhD retweeted
We offer all four types of molecular biomarker tumor testing for CNS tumors, which, in addition to DNA methylation profile, includes mutations, fusions, and copy number variants.
Learn more.
bit.ly/4dMxwoo
Maria Willrich, PhD retweeted
Join Dr. David M. Nathan today at 5 p.m. Pacific Time as he reflects on some of the most groundbreaking discoveries and innovations in diabetes care. ow.ly/ikAG50ZsZci
Maria Willrich, PhD retweeted
Interleukin-6 (IL-6) has a causal role in #cvCAD and the atherogenic inflammatory cascade, by sitting upstream of the hepatic CRP and downstream of NLRP3 inflammasome and IL-1β.
More on IL-6 as a predictor of CV risk assessment ➡️ bit.ly/4wjgrdH #ACCPrev #cvPrev
Maria Willrich, PhD retweeted
Come to the Disruptive Technology Award competition tomorrow, July 27, to see innovative diagnostic technologies from three finalists put to the test! The winner will be announced at the end of the event. ow.ly/K5pe50ZsZrm
Maria Willrich, PhD retweeted
Swing by the Student Poster Competition tomorrow, July 27, from 2:30–4 p.m. to support student research. Judges evaluate poster competitors on scientific quality, clarity, and poster presentation.
ow.ly/aPyz50ZsZtK
Maria Willrich, PhD retweeted
For individuals affected by multiple sclerosis, early diagnosis is critical.
Mayo Clinic Laboratories’ multiple sclerosis testing delivers faster, more definitive results, enabling earlier treatment decisions and improved patient outcomes.
Learn more.
bit.ly/4sAOED5
Maria Willrich, PhD retweeted
Researchers sent the same resume to an AI hiring tool twice. Same qualifications. Same experience. Same skills. One version was written by a real human. The other was rewritten by ChatGPT.
The AI picked the ChatGPT version 97.6% of the time.
A team from the University of Maryland, the National University of Singapore, and Ohio State just published the receipt. They took 2,245 real human-written resumes pulled from a professional resume site from before ChatGPT existed, so the human writing was actually human. Then they had seven of the most-used AI models in the world rewrite each one. GPT-4o. GPT-4o-mini. GPT-4-turbo. LLaMA 3.3-70B. Qwen 2.5-72B. DeepSeek-V3. Mistral-7B.
Then they asked each AI to pick the better resume. Every model picked itself.
GPT-4o hit 97.6%. LLaMA-3.3-70B hit 96.3%. Qwen-2.5-72B hit 95.9%. DeepSeek-V3 hit 95.5%. The real human almost never won.
Then the researchers tried the obvious objection. Maybe the AI is just better at writing. So they had real humans grade the resumes for actual quality and ran the experiment again, controlling for it. The result was worse. Each AI kept picking itself even when human judges rated the human-written version as clearer, more coherent, and more effective.
It gets worse. The AIs do not just prefer AI over humans. They prefer themselves over other AIs. DeepSeek-V3 picked its own resumes 69% more often than LLaMA's. GPT-4o picked its own 45% more often than LLaMA's. Each model can recognize and reward its own dialect.
Then the researchers ran the simulation that ends careers. Same job. 24 occupations. Same qualifications. The only variable was whether the candidate used the same AI as the screening tool. Candidates using that AI were 23% to 60% more likely to be shortlisted. Worst gap was in sales, accounting, and finance.
99% of large companies now run AI on incoming resumes. Most of them use GPT-4o. The paper just proved GPT-4o picks GPT-4o 97.6% of the time.
If you wrote your own cover letter this week, you did not lose to a better candidate. You lost to a worse candidate who paid OpenAI 20 dollars.
Your qualifications do not matter if the AI prefers its own handwriting over yours.
Maria Willrich, PhD retweeted
Our Laboratory Medicine Grand Rounds on Wednesday, April 22 at 12 PM ET features @malicewi, PhD, of the Mayo Clinic College of Medicine and Science. shorturl.at/T8NWD
Maria Willrich, PhD retweeted
Many thanks to @malicewi, PhD, of the Mayo Clinic College of Medicine and Science, for presenting today’s Laboratory Medicine Grand Rounds. Here is Dr. Willrich, left, with her host, @ClinChemJoe, PhD, DABCC, of @YaleMed
Maria Willrich, PhD retweeted
Multiple sclerosis can be difficult to diagnose, but early diagnosis is critical. Our testing cascade delivers faster, more definitive results, enabling earlier treatment decisions and improved patient outcomes.
Learn more.
bit.ly/4sAOED5
Maria Willrich, PhD retweeted
Our Mayo buildings are lit up to celebrate World #Myeloma Day today 🎗️. A true testament to the unbelievable progress made in the field. @IMFnurseMyeloma
@VincentRK @Taxkourel @YiLinMDPhD
Maria Willrich, PhD retweeted
📍ASH guidelines on diagnosis of AL amyloidosis 2026. ➡️Two years of meetings and collaboration with an interdisciplinary international team.
The 2024 McDonald criteria for multiple sclerosis is out. A companion paper highlighting the positive CSF is linked and supports the use of kappa free light chain index as an alternative to oligoclonal banding, added to the new criteria. sciencedirect.com/science/ar…
Maria Willrich, PhD retweeted
Dr @malicewi presenting ICI Associated AKI and ICI levels
@MayoClinicNeph
@onconephsociety
@LeticiaRolonMD
We launched guselkumab serum concentration testing by LC-MS. This monoclonal antibody targets IL-23 and has shown promising response in inflammatory bowel disease. Fun fact- it’s an IgG lambda, not an IgG kappa like the vast majority of t-mabs. mayocliniclabs.com/test-cata…
Maria Willrich, PhD retweeted
Please welcome the 2025 ADLM Featured Voices who will share their experiences throughout ADLM 2025. Follow them on your favorite social media platform at #ADLM2025.
Maria Willrich, PhD retweeted
Join us for the Opening Mixer tonight from 6:30-8 p.m. at the Lakeside Center Terrace, McCormick Place. Welcome to #ADLM2025!
Maria Willrich, PhD retweeted
Press Release International Myeloma Foundation (IMF) to Honor 2025 Kyle and Durie Achievement Awardees, Dr. Sagar Lonial and Dr. Sonja Zweegman
globenewswire.com/news-relea…


























